Rivaroxaban: A direct factor Xa inhibitor for VTE prophylaxis in patients undergoing total knee or hip replacement surgery

Formulary

Volumn 44, Issue 8, 2009, Pages 226-236

  Nunokawa, Nikki ^a   Wong, Heather ^a   Song, Jessica C ^a,b  

^a UNIVERSITY OF THE PACIFIC   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALUMINUM HYDROXIDE; APIXABAN; DABIGATRAN; DIGOXIN; ENOXAPARIN; FONDAPARINUX; MAGNESIUM HYDROXIDE; NAPROXEN; RANITIDINE; RIVAROXABAN; WARFARIN;

ACUTE CORONARY SYNDROME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; BLEEDING; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; VENOUS THROMBOEMBOLISM;

EID: 77952037752     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Koda-Kimble MA, Young LY, Alldredge BK, et al, eds. Applied Therapeutics: The Clinical Use of Drugs. 9th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2009.
2. Haines ST, Nutescu EA. Venous thromboembolism. In: Chisholm-Burns MA, Wells BG, Schwinghammer TL, et al, eds. Pharmacotherapy Principles & Practice. New York: McGraw-Hill Medical; 2008:133-160.
3. Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 suppl):71-109.
4. Lovenox [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; 2008.
5. Arixtra [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2008.
6. Warfarin [prescribing information]. St. Louis, MO: MallinckrodtInc.; 2007.
7. Ezekowitz MD, Connolly S, Parekh A, et al. Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009;157:805-810.
8. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxa-parin for the prevention of venous thromboembolism after total knee replacement: The REMODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
9. Baetz BE, Spinier SA. Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008;28:1354-1373.
10. Carreiro J, Ansell J. Apixaban, an oral direct factor Xa inhibitor: Awaiting the verdict. Expert Opin Investig Drugs. 2008;17:1937-1945.
11. Bayer Health Care. About rivaroxaban clinical studies. www.xarelto.com/html/press/pdf/About-Rivaroxaban-Clinical-Studies.pdf. Accessed July 22, 2009.
12. U.S. FDA Advisory Committee supports favorable benefit-risk profile of Bayer's rivaroxaban [press release]. Leverkusen, Germany: Bayer HealthCare; March 19, 2009.
13. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2008;28:380-386.
14. Perzbom E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 - an oral, direct factor Xa inhibitor. J Thromb Haemost. 2005;3:514-521.
15. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
16. Samama MM, Le Hem L, Guinet C, Perzborn E, Martinoli J-L, Depasse F. Effects of the novel, oral, direct factor Xa inhibitor rivaroxaban on coagulation assays [abstract]. Poster presented at: American Society of Hematology (ASH) 50th Annual Meeting and Exposition; December 6-9, 2008; San Francisco, CA. Abstract 3028.
17. Kubitza D, Becka M, Wensig G, et al. Single dose escalation study investigating the pharmacodynamics, safety, and pharmacokinetics of BAY 59-7939 an oral, direct factor Xa inhibitor in healthy male subjects [abstract]. Blood. 2003;102: Abstract 3010.
18. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-880.
19. Xarelto [prescribing information]. Leverkusen, Germany: Bayer Healthcare AG; 2008.
20. Weinz C, Buetehorn U, Daehler HP, et al. Pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - in rats and dogs. Xenobiotica. 2005;35:891-910.
21. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol. 2006;46:549-558.
22. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. J Clin Pharmacol 2007;47: 218-226.
23. [erratum in J Clin Pharmacol. 2008;48:1366-1367]
24. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-2775.
25. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: A double-blind, randomised controlled trial. Lancet. 2008;372:31-39.
26. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-2786.
27. Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD 4): A randomised trial. Lancet. 2009;373:1673-1680.
28. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2007;29:155-165.
29. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Rivaroxaban (BAY 59-7939) - an oral, direct factor Xa inhibitor - has no clinically relevant interaction with naproxen. Br J CHn Pharmacol. 2007;63:469-476.
30. Kubitza D, Becka M, Mueck W, Zuehlsdorf M. Safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban - an oral, direct factor Xa inhibitor - are not affected by aspirin. J Clin Pharmacol. 2006;46:981-990.
31. Kubitza D, Becka M, Zuehlsdorf M, et al. No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7379 and digoxin [abstract]. J Clin Pharmacol. 2006;6:702.